Opinion|Videos|May 23, 2024
Tailoring Treatment: Patient Factors Guiding First-Line Medication Selection for Older Adults with Type 2 Diabetes
Drs Medha Munshi and James Bailey offer insights into navigating the type 2 diabetes treatment landscape. They emphasize the importance of prioritizing cardiovascular and renal outcomes when selecting treatments for older adult populations.
Advertisement
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Advertisement
Advertisement
Trending on Patient Care Online
1
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
2
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
3
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
4
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
5